Physician profile
James J Park
NPI 1306871421
$43,698.92
in general payments reported to CMS, 2019-2025
45 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,911 · 2020: $8,033 · 2021: $8,266 · 2022: $8,537 · 2023: $9,286 · 2024: $5,796 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $11K · Food and Beverage: $4,463 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $11,375.00 |
| Food and Beverage | $4,462.66 |
| Education | $115.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $31,191.67 | 2020-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $1,627.39 | 2019-2025 | |
| Emd Serono, INC. | $1,287.18 | 2019-2025 | Mavenclad, Mavenclad |
| Medtronic USA, INC. | $1,183.84 | 2019 | |
| Abbvie INC. | $1,002.88 | 2021-2024 | |
| Genzyme Corporation | $718.81 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $691.56 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $673.41 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $579.86 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Biogen, INC. | $537.71 | 2019-2023 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $506.63 | 2019-2025 | Briviact |
| Mdd US Operations, LLC | $412.01 | 2021-2024 | Gocovri, Gocovri |
| Allergan, INC. | $359.60 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $327.50 | 2021-2023 | Ingrezza, Ongentys |
| Eisai INC. | $287.19 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.